Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A unique group of rare tumors of the central nervous system that affect mainly children and adolescents. Their morphologic and biologic profile corresponds to that of homologous germ cell tumors that arise in the gonads and in other extragonadal sites. Representative examples include: germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.
Biomarker and diagnostic research for central nervous system germ cell tumor has been reported in the published literature.
2 clinical trials registered. Interventions under study include other interventions and procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
168 publications have been identified in PubMed for central nervous system germ cell tumor. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (29%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 52 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 9:00 AM UTC
Laboratory research | 48 | 29% |
Testing and diagnosis research | 16 | 10% |
Clinical study results | 16 | 10% |
New treatment approaches | 15 | 9% |
Patient case studies | 10 | 6% |
Disease patterns and progression | 10 | 6% |
Other research | 1 | 1% |
Oztek MA (2026). [PMID: 41274772](https://pubmed.ncbi.nlm.nih.gov/41274772/). *Neuroimaging clinics of North America*. [Case Report / Case Series]
Faure Conter C (2026). [PMID: 42115464](https://pubmed.ncbi.nlm.nih.gov/42115464/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Ozono I (2026). [PMID: 41189118](https://pubmed.ncbi.nlm.nih.gov/41189118/). *Jpn J Clin Oncol*. [Diagnostic / Biomarker]
Ohtani K (2026). [PMID: 42038058](https://pubmed.ncbi.nlm.nih.gov/42038058/). *NMC Case Rep J*. [Case Report / Case Series]
Romanowicz A (2026). [PMID: 41399659](https://pubmed.ncbi.nlm.nih.gov/41399659/). *Biochem Med (Zagreb)*. [Review / Meta-Analysis]
Miller HK (2026). [PMID: 42111021](https://pubmed.ncbi.nlm.nih.gov/42111021/). *Neurooncol Pract*. [Clinical Trial Publication]
Al Fidawi N (2026). [PMID: 41718120](https://pubmed.ncbi.nlm.nih.gov/41718120/). *Med Sci (Basel)*. [Review / Meta-Analysis]
Cui S (2026). [PMID: 41448554](https://pubmed.ncbi.nlm.nih.gov/41448554/). *Biochimica et biophysica acta. Reviews on cancer*. [Review / Meta-Analysis]
Levine AB (2026). [PMID: 41117845](https://pubmed.ncbi.nlm.nih.gov/41117845/). *Neuro-oncology*. [Epidemiology / Natural History]
Wesseling P (2026). [PMID: 40887057](https://pubmed.ncbi.nlm.nih.gov/40887057/). *Brain pathology (Zurich, Switzerland)*. [Diagnostic / Biomarker]